Most recent update: Monday, January 20, 2020 - 11:48

Bariatric News - Cookies & privacy policy

You are here

Atrial fibrillation

Antiarrhythmic medications less effective in patients with obesity

Class I drug treatment showed increased rates of AFib reoccurrences in obese patients compared with patients without obesity

Researchers at the University of Illinois at Chicago have shown for the first that some antiarrhythmic medications used to treat atrial fibrillation are less effective in patients who are obese. Atrial fibrillation (AFib), the most common type of irregular heartbeat, and it is associated with increased mortality. While researchers have identified a causal link between obesity and AFib, the underlying mechanism of how obesity contributes to the heart arrhythmia is still unknown. The results of this study, 'Association Between Obesity-Mediated Atrial Fibrillation and Therapy With Sodium Channel Blocker Antiarrhythmic Drugs', which followed more than 300 patients in the UIC AFib Registry, were published in JAMA Cardiology.

Dawood Darbar

According to Dr Dawood Darbar, senior author on the study, response to current antiarrhythmic drug treatment for AFib is highly variable and unpredictable, and medication selection depends on the treating physician. There are no guidelines to suggest whether Class I drugs - which work on sodium channels in the heart to regulate heartbeat - or Class III drugs - those that target potassium channels - work best in which patients. Previously, it was assumed that both antiarrhythmic drugs were equally effective in preventing reoccurrences of AFib.

"This is the first time anyone has shown that there is a differential response to antiarrhythmic drugs for AFib," said Darbar, professor and head of cardiology at the College of Medicine. "As 50% of the patients in our AFib Registry are obese, this provided us with a unique opportunity to determine whether obesity affected response to drug treatment for AFib. Our study provides new information that physicians can use to guide their decisions for obese patients with AFib."

In the new study, Darbar and his colleagues have shown that Class I drug treatment showed increased rates of AFib reoccurrences in obese patients compared with patients without obesity - approximately 30% of obese patients had AFib reoccurrence, compared with only 6% of patients without obesity. This effect was not seen among patients treated with Class III drugs.

"This may particularly impact the health of ethnic minorities who are more likely to experience obesity," he added.

More than 50% of the obese patients in the study were part of an ethnic minority group. While the prevalence of AFib is low in ethnic minority populations, their outcomes are graver.

"With the obesity epidemic increasing, it leaves these populations at risk," Darbar said. "Having treatment options to better manage AFib would greatly improve quality of life and could prevent the risk of serious complications, like stroke, which can cause early death."

Darbar and his colleagues ultimately hope to uncover the underlying mechanism of how obesity hinders Class I antiarrhythmic drugs and find new and targeted AFib treatment options.

Want more stories like this? Subscribe to Bariatric News!

Bariatric News
Keep up to date! Get the latest news in your inbox. NOTE: Bariatric News WILL NOT pass on your details to 3rd parties. However, you may receive ‘marketing emails’ sent by us on behalf of 3rd parties.